This activity is intended for medical oncologists, radiation oncologists, nurses and other healthcare providers involved in the treatment of lymphomas and chronic lymphocytic leukemia (CLL).
OVERVIEW OF ACTIVITY
Management of hematologic cancers is one of the most rapidly evolving fields in medicine. Cytotoxic chemotherapies, autologous and/or allogeneic hematopoietic stem cell transplant and biologic or molecular-targeted therapies have been the focus of treatment algorithms designed to assist clinicians in the clinical care of patients with hematologic cancer. Despite the existence of such tools, many areas of controversy persist within the academic and community settings, especially within the area of lymphomas and CLL. The recent arrival of novel agents and the emergence of extensive practice-changing clinical trial data have created clinical scenarios in which multiple treatment options may be available but the optimal strategy is highly debatable. To bridge the gap between research and patient care, this CME activity will use the perspectives of clinical investigators on key challenges and controversies in lymphomas and CLL to address the existing management uncertainties of clinician learners and help keep them up to date in a continuously evolving therapeutic environment.
LEARNING OBJECTIVES
- Review patient and disease characteristics that influence faculty recommendations regarding the up-front treatment of follicular lymphoma (FL), and consider this information when caring for such patients.
- Evaluate the impact of age and time to relapse on faculty preferences for second-line therapy for patients with FL.
ACCREDITATION STATEMENT
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
CME credit is no longer available for this issue
CREDIT DESIGNATION STATEMENT
CME credit is no longer available for this issue
AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
CME credit is no longer available for this issue
HOW TO USE THIS CME ACTIVITY
This CME activity consists of a text component.
CME credit is no longer available for this issue
CONTENT VALIDATION AND DISCLOSURES
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.
FACULTY — The following faculty (and their spouses/partners) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process:
Christopher Flowers, MD, MS
Associate Professor of Hematology and Medical Oncology
Emory School of Medicine
Winship Cancer Institute
Atlanta, Georgia
Consulting Agreements: Celgene Corporation, OptumRx Inc; Contracted Research: Acerta Pharma, Celgene Corporation, Gilead Sciences Inc, Infinity Pharmaceuticals Inc, Janssen Biotech Inc, Onyx Pharmaceuticals, an Amgen subsidiary, Pharmacyclics LLC, an AbbVie Company, Takeda Oncology, TG Therapeutics Inc; Unpaid Consulting Agreements: Genentech BioOncology, Takeda Oncology.
Brad S Kahl, MD
Professor of Medicine
Washington University School of Medicine
St Louis, Missouri
Advisory Committee: Roche Laboratories Inc, Takeda Oncology; Consulting Agreements: Bristol-Myers Squibb Company, Celgene Corporation, Genentech BioOncology; Contracted Research: Abbott Laboratories.
John P Leonard, MD
Richard T Silver Distinguished Professor of Hematology and Medical Oncology
Associate Dean for Clinical Research
Weill Cornell Medical College
New York, New York
Consulting Agreements: Bayer HealthCare Pharmaceuticals, Celgene Corporation, Cephalon Inc.
Loretta J Nastoupil, MD
Assistant Professor
Department of Lymphoma/Myeloma, Division of Cancer Medicine
Director, Lymphoma Outcomes Database
The University of Texas MD Anderson Cancer Center
Houston, Texas
Advisory Committee: Gilead Sciences Inc, Janssen Biotech Inc, TG Therapeutics Inc; Consulting Agreement: Gilead Sciences Inc; Contracted Research: Abbott Laboratories, Celgene Corporation, Genentech BioOncology, Janssen Biotech Inc, TG Therapeutics Inc.
Jeff Sharman, MD
Medical Director of Hematology Research
The US Oncology Network
Director of Research
Willamette Valley Cancer Institute
Eugene, Oregon
Advisory Committee: Acerta Pharma, Celgene Corporation, Genentech BioOncology, Pfizer Inc; Consulting Agreements: Acerta Pharma, Celgene Corporation, Genentech BioOncology, Gilead Sciences Inc, Juno Therapeutics, Pfizer Inc; Contracted Research: Acerta Pharma, Bristol-Myers Squibb Company, Celgene Corporation, Genentech BioOncology, Gilead Sciences Inc, Merck, Onyx Pharmaceuticals, an Amgen subsidiary, Pfizer Inc, Roche Laboratories Inc; Speakers Bureau: Gilead Sciences Inc.
Mitchell R Smith, MD, PhD
Director of Lymphoid Malignancies Program at Taussig Cancer Institute
Cleveland Clinic
Cleveland, Ohio
Consulting Agreements: Celgene Corporation, Genentech BioOncology, Spectrum Pharmaceuticals Inc; Contracted Research: Abbott Laboratories, Takeda Oncology.
Sonali M Smith, MD
Associate Professor
Section of Hematology/Oncology
Director, Lymphoma Program
The University of Chicago
Chicago, Illinois
Advisory Committee: Roche Laboratories Inc; Consulting Agreements: Celgene Corporation, Genentech BioOncology, Pharmacyclics LLC, an AbbVie Company.
Michael E Williams, MD, ScM
Byrd S Leavell Professor of Medicine
Chief, Hematology/Oncology Division
University of Virginia School of Medicine
Charlottesville, Virginia
Advisory Committee and Consulting Agreements: Celgene Corporation, Gilead Sciences Inc, Takeda Oncology, TG Therapeutics Inc; Contracted Research: Allos Therapeutics, Celgene Corporation, Gilead Sciences Inc, Takeda Oncology.
EDITOR — Dr Love is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Acerta Pharma, Agendia Inc, Amgen Inc, Array BioPharma Inc, Astellas Pharma Global Development Inc, AstraZeneca Pharmaceuticals LP, Baxalta Inc, Bayer HealthCare Pharmaceuticals, Biodesix Inc, bioTheranostics Inc, Boehringer Ingelheim Pharmaceuticals Inc, Boston Biomedical Pharma Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, CTI BioPharma Corp, Daiichi Sankyo Inc, Dendreon Pharmaceuticals Inc, Eisai Inc, Exelixis Inc, Foundation Medicine, Genentech BioOncology, Genomic Health Inc, Gilead Sciences Inc, ImmunoGen Inc, Incyte Corporation, Infinity Pharmaceuticals Inc, Janssen Biotech Inc, Jazz Pharmaceuticals Inc, Lilly, Medivation Inc, Merck, Merrimack Pharmaceuticals Inc, Myriad Genetic Laboratories Inc, NanoString Technologies, Natera Inc, Novartis Pharmaceuticals Corporation, Novocure, Onyx Pharmaceuticals, an Amgen subsidiary, Pharmacyclics LLC, an AbbVie Company, Prometheus Laboratories Inc, Regeneron Pharmaceuticals, Sanofi, Seattle Genetics, Sigma-Tau Pharmaceuticals Inc, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Taiho Oncology Inc, Takeda Oncology, Teva Oncology, Tokai Pharmaceuticals Inc and VisionGate Inc.
RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS — The scientific staff and reviewers for Research To Practice have no relevant conflicts of interest to disclose.
This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.
This activity is supported by educational grants from Celgene Corporation, Genentech BioOncology, Gilead Sciences Inc, Janssen Biotech Inc, Pharmacyclics LLC, an AbbVie Company and Takeda Oncology.
Hardware/Software Requirements:
A high-speed Internet connection
A monitor set to 1280 x 1024 pixels or more
Internet Explorer 7 or later, Firefox 3.0 or later, Chrome, Safari 3.0 or later
Adobe Flash Player 10.2 plug-in or later
Adobe Acrobat Reader
(Optional) Sound card and speakers for audio
Last review date: October 2016
Expiration date: October 2017